Background: A major problem with HCC surveillance is the lack of reliable biomarkers, alpha-fetoprotien (AFP) is the most widely used biomarker for HCC surveillance, However not all HCCs secrete AFP; furthermore AFP may be elevated in patients with chronic liver disease in the absence of HCC. Serum alpha-l-fucosidase, SCCA-IgM have been found to be useful markers in diagnosing HCCAim of the work: to evaluate the role of serum SCCA-IgM& Alpha-L-fucosidase as non invasive biomarkers in diagnosis of hepatocellular carcinoma.Subjects and Methods: this study conducted on total number of 90 subjects divided as follows: 30 cirrhotic patients diagnosed by abdominal ultrasound, 40 patients with HCC diagnosed with abdominal U/S &CT scan, and 20 healthy subjects taken as control group.Results: serum SCCA-IgM level was significantly higher in HCC group when compared to cirrhosis & control group with P value (P = 0.000), At cut-off value of 233 AU/mL SCCA-IgM showed sensitivity 87.5%, & specificity of 66%, area under the ROC curve (95% CI) was 0.86 (0.76-0.95), serum alpha-l-fucosidase was significantly higher in HCC group when compared to cirrhosis & control group with P value (P = 0.000) ,At cut-off value of 25 U/L, alpha-l-fucosidase showed sensitivity 87.5%, & specificity of 98%, area under the ROC curve (95% CI) was 0.892(0.8-0.97), AFP was significantly higher in HCC group when compared to control group with P value (P = 0.000) but on comparing serum AFP level between HCC &cirrhotic groups there was no statistical significant difference observed (P =0.09) , At cut-off value of 48 U/L AFP showed sensitivity 70%, & specificity of 53.3%, area under the ROC curve (95% CI) was 0.618(0.48-0.75), Conclusion: the significant difference observed for squamous cell carcinoma antigen IgM and Alpha-L-fucosidase between HCC and liver cirrhotic patients suggests their use as potential diagnostic tools and allows us to identify a new group of HCC patients, even in the absence of increased AFP levels.